PHILADELPHIA -- Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient’s immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
